SCHEMBL2865593

SCHEMBL2865593

OCc1ccc2cccnc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 1/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
KMT2A Q03164 1/20 0.58
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
HTT P42858 1/20 0.53
NR4A2 P43354 1/20 0.53
RAB9A P51151 2/20 0.51
TP53 P04637 1/20 0.51
RECQL P46063 1/20 0.51
CYP3A4 P08684 2/20 0.50
RIPK1 Q13546 1/20 0.47
HDAC6 Q9UBN7 1/20 0.46
CYSLTR1 Q9Y271 2/20 0.44
CBFB Q13951 2/20 0.44
GPBAR1 Q8TDU6 1/20 0.44
PDE10A Q9Y233 1/20 0.44
EGLN1 Q9GZT9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19283123 0.98 ALDH1A1 (0.56) ALDH1A1MEN1CASP1CASP7KMT2A
Ammonia Solution, Strong SCHEMBL27721873 0.98 ALDH1A1 (0.56) ALDH1A1MEN1CASP1CASP7KMT2A
Ethane SCHEMBL9847468 0.96 ALDH1A1 (0.55) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL20592948 0.85 ALDH1A1 (0.55) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL187244 0.85 NPC1 (0.57) ALDH1A1MEN1CASP1KMT2AHTT
Hydrochloric Acid SCHEMBL9256396 0.83 NPC1 (0.55) ALDH1A1MEN1CASP1KMT2AHTT
SCHEMBL6360170 0.82 ALDH1A1 (0.51) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL9447104 0.81 NR4A2 (0.58) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL464410 0.81 ALDH1A1 (0.58) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL1495700 0.81 ALDH1A1 (0.53) ALDH1A1MEN1CASP1CASP7KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1178938-C 1,2-annelated quinoline derivatives ղɭҩҵ���޹�˾ 2004-12-08 CN claimed
CN-1331693-A 1,2-annelated quinoline derivatives JANSSEN PHARMACEUTICA NV (BE) 2002-01-16 CN claimed
CN-1100414-A Preparation of pharmaceutical compound containing novel derivative of leukol SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-03-22 CN claimed
CN-1027368-C Process for preparing substituted quinoline derivatives SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-01-11 CN claimed
CN-1035501-A PROCESS FOR PREPARING SUBSTITUTED QUINOLINE DERIVATIVES SMITHKLINE BECKMAN INTERCREDIT (NL) 1989-09-13 CN claimed
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2025-04-10 US disclosed
US-12157734-B2 Sulfoximine glycosidase inhibitors ASCENEURON SA (CH) 2024-12-03 US disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 CN disclosed
CN-110770226-B Sulfoximine glycosidase inhibitors 阿森纽荣股份公司 2023-11-10 CN disclosed
CN-108137542-B Pyridone dicarboxamides as bromodomain inhibitors 葛兰素史克知识产权第二有限公司 2023-10-27 CN disclosed
CN-115515956-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-23 CN disclosed
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-06-09 US disclosed
US-5441954-A Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells JANSSEN PHARMACEUTICA N. V. (BE) 1995-08-15 US disclosed
EP-0371564-B1 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-07-12 EP disclosed
CN-1100414-A Preparation of pharmaceutical compound containing novel derivative of leukol SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-03-22 CN disclosed
CN-1027368-C Process for preparing substituted quinoline derivatives SMITHKLINE BECKMAN INTERCREDIT (NL) 1995-01-11 CN disclosed
US-5268380-A Therapy for keratinization in mammals JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-07 US disclosed
US-5185346-A Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents HANSSEN PHARMACEUTICA (BE) 1993-02-09 US disclosed
EP-0371564-A2 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-06 EP disclosed
CN-1035501-A PROCESS FOR PREPARING SUBSTITUTED QUINOLINE DERIVATIVES SMITHKLINE BECKMAN INTERCREDIT (NL) 1989-09-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157734-B2 Sulfoximine glycosidase inhibitors ENGASE, BACE1, GAA ALDH1A1 862/4885MEN1 4011/4885CASP1 3987/4885
US-20220177470-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA ALDH1A1 862/4885MEN1 4011/4885CASP1 3987/4885
US-20250115604-A1 SULFOXIMINE GLYCOSIDASE INHIBITORS ENGASE, BACE1, GAA ALDH1A1 955/4885MEN1 3872/4885CASP1 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.